News & Updates

IV sotalol administered rapidly as a loading dose to initiate oral sotalol therapy is feasible and safe for rhythm control in individuals with atrial fibrillation (AF), the DASH-AF study finds.

In patients with advanced chronic kidney disease (CKD), discontinuing renin–angiotensin system (RAS) inhibitor therapy does not slow down decline in estimated glomerular filtration rate (eGFR), a recent trial showed.

Food appears to affect the pharmacokinetics of diazepam dosed via nasal spray, with absorption being markedly decreased and delayed, according to an open-label crossover study.

Targeted oral naltrexone results in a significant reduction in drinking outcomes among sexual and gender minority men (SGM) with mild to moderate alcohol use disorder (AUD) during treatment, reports a study. This beneficial effect persists up to 6 months post-treatment.

In individuals with Wilson disease (WD), a rare disease of copper metabolism, ALXN1840 led to significantly greater copper mobilization compared with standard of care (SoC), findings from a rater-blinded phase III study have shown.